Glycosylation  ||| S:0 E:14 ||| NNP
of  ||| S:14 E:17 ||| IN
proteinase  ||| S:17 E:28 ||| CD
3  ||| S:28 E:30 ||| CD
( ||| S:30 E:31 ||| -LRB-
PR3 ||| S:31 E:34 ||| NNP
)  ||| S:34 E:36 ||| -RRB-
is  ||| S:36 E:39 ||| VBZ
not  ||| S:39 E:43 ||| RB
required  ||| S:43 E:52 ||| VBN
for  ||| S:52 E:56 ||| IN
its  ||| S:56 E:60 ||| PRP$
reactivity  ||| S:60 E:71 ||| NN
with  ||| S:71 E:76 ||| IN
antineutrophil  ||| S:76 E:91 ||| JJ
cytoplasmic  ||| S:91 E:103 ||| JJ
antibodies  ||| S:103 E:114 ||| NNS
( ||| S:114 E:115 ||| -LRB-
ANCA ||| S:115 E:119 ||| NNP
)  ||| S:119 E:121 ||| -RRB-
in  ||| S:121 E:124 ||| IN
Wegener ||| S:124 E:131 ||| NNP
's  ||| S:131 E:134 ||| POS
granulomatosis  ||| S:134 E:149 ||| VBG
The  ||| S:149 E:153 ||| DT
glycosylation  ||| S:153 E:167 ||| JJ
status  ||| S:167 E:174 ||| NN
of  ||| S:174 E:177 ||| IN
autoantigens  ||| S:177 E:190 ||| NN
appears  ||| S:190 E:198 ||| VBZ
to  ||| S:198 E:201 ||| TO
be  ||| S:201 E:204 ||| VB
crucial  ||| S:204 E:212 ||| JJ
for  ||| S:212 E:216 ||| IN
the  ||| S:216 E:220 ||| DT
pathogenesis  ||| S:220 E:233 ||| NN
of  ||| S:233 E:236 ||| IN
some  ||| S:236 E:241 ||| DT
autoimmune  ||| S:241 E:252 ||| JJ
diseases ||| S:252 E:260 ||| NNS
,  ||| S:260 E:262 ||| ,
since  ||| S:262 E:268 ||| IN
carbohydrates  ||| S:268 E:282 ||| NNS
play  ||| S:282 E:287 ||| VBP
a  ||| S:287 E:289 ||| DT
crucial  ||| S:289 E:297 ||| JJ
role  ||| S:297 E:302 ||| NN
in  ||| S:302 E:305 ||| IN
the  ||| S:305 E:309 ||| DT
distinction  ||| S:309 E:321 ||| NN
of  ||| S:321 E:324 ||| IN
self  ||| S:324 E:329 ||| NN
from  ||| S:329 E:334 ||| IN
non-self ||| S:334 E:342 ||| JJ
.  ||| S:342 E:344 ||| .
Proteinase  ||| S:344 E:355 ||| NNP
3  ||| S:355 E:357 ||| CD
( ||| S:357 E:358 ||| -LRB-
PR3 ||| S:358 E:361 ||| NNP
) ||| S:361 E:362 ||| -RRB-
,  ||| S:362 E:364 ||| ,
the  ||| S:364 E:368 ||| DT
main  ||| S:368 E:373 ||| JJ
target  ||| S:373 E:380 ||| NN
antigen  ||| S:380 E:388 ||| NN
for  ||| S:388 E:392 ||| IN
anti-neutrophil  ||| S:392 E:408 ||| JJ
cytoplasmic  ||| S:408 E:420 ||| JJ
antibodies  ||| S:420 E:431 ||| NNS
( ||| S:431 E:432 ||| -LRB-
ANCA ||| S:432 E:436 ||| NNP
)  ||| S:436 E:438 ||| -RRB-
in  ||| S:438 E:441 ||| IN
patients  ||| S:441 E:450 ||| NNS
with  ||| S:450 E:455 ||| IN
Wegener ||| S:455 E:462 ||| NNP
's  ||| S:462 E:465 ||| POS
granulomatosis  ||| S:465 E:480 ||| NN
( ||| S:480 E:481 ||| -LRB-
WG ||| S:481 E:483 ||| NNP
) ||| S:483 E:484 ||| -RRB-
,  ||| S:484 E:486 ||| ,
contains  ||| S:486 E:495 ||| VBZ
two  ||| S:495 E:499 ||| CD
Asn-linked  ||| S:499 E:510 ||| JJ
glycosylation  ||| S:510 E:524 ||| JJ
sites ||| S:524 E:529 ||| NNS
.  ||| S:529 E:531 ||| .
The  ||| S:531 E:535 ||| DT
present  ||| S:535 E:543 ||| JJ
study  ||| S:543 E:549 ||| NN
explores  ||| S:549 E:558 ||| VBZ
the  ||| S:558 E:562 ||| DT
influence  ||| S:562 E:572 ||| NN
of  ||| S:572 E:575 ||| IN
the  ||| S:575 E:579 ||| DT
glycosylation  ||| S:579 E:593 ||| JJ
status  ||| S:593 E:600 ||| NN
of  ||| S:600 E:603 ||| IN
PR3  ||| S:603 E:607 ||| CD
on  ||| S:607 E:610 ||| IN
the  ||| S:610 E:614 ||| DT
PR3  ||| S:614 E:618 ||| JJ
recognition  ||| S:618 E:630 ||| NN
by  ||| S:630 E:633 ||| IN
ANCA  ||| S:633 E:638 ||| NNP
in  ||| S:638 E:641 ||| IN
a  ||| S:641 E:643 ||| DT
well  ||| S:643 E:648 ||| RB
characterized  ||| S:648 E:662 ||| VBN
population  ||| S:662 E:673 ||| NN
of  ||| S:673 E:676 ||| IN
patients  ||| S:676 E:685 ||| NNS
with  ||| S:685 E:690 ||| IN
WG ||| S:690 E:692 ||| NNP
.  ||| S:692 E:694 ||| .
Forty-four  ||| S:694 E:705 ||| JJ
patients  ||| S:705 E:714 ||| NNS
with  ||| S:714 E:719 ||| IN
WG  ||| S:719 E:722 ||| NNP
( ||| S:722 E:723 ||| -LRB-
459  ||| S:723 E:727 ||| CD
serum  ||| S:727 E:733 ||| CD
samples ||| S:733 E:740 ||| NNS
)  ||| S:740 E:742 ||| -RRB-
who  ||| S:742 E:746 ||| WP
participated  ||| S:746 E:759 ||| VBD
in  ||| S:759 E:762 ||| IN
a  ||| S:762 E:764 ||| DT
multicenter  ||| S:764 E:776 ||| JJ
randomized  ||| S:776 E:787 ||| JJ
trial ||| S:787 E:792 ||| NN
,  ||| S:792 E:794 ||| ,
were  ||| S:794 E:799 ||| VBD
tested  ||| S:799 E:806 ||| VBN
by  ||| S:806 E:809 ||| IN
capture  ||| S:809 E:817 ||| JJ
ELISA  ||| S:817 E:823 ||| NN
for  ||| S:823 E:827 ||| IN
ANCA  ||| S:827 E:832 ||| NNP
against  ||| S:832 E:840 ||| IN
PR3  ||| S:840 E:844 ||| NNP
and  ||| S:844 E:848 ||| CC
deglycosylated  ||| S:848 E:863 ||| JJ
recombinant  ||| S:863 E:875 ||| JJ
variants  ||| S:875 E:884 ||| NN
of  ||| S:884 E:887 ||| IN
PR3 ||| S:887 E:890 ||| CD
.  ||| S:890 E:892 ||| .
The  ||| S:892 E:896 ||| DT
patients  ||| S:896 E:905 ||| NNS
were  ||| S:905 E:910 ||| VBD
followed  ||| S:910 E:919 ||| VBN
for  ||| S:919 E:923 ||| IN
a  ||| S:923 E:925 ||| DT
median  ||| S:925 E:932 ||| NN
of  ||| S:932 E:935 ||| IN
27  ||| S:935 E:938 ||| CD
months ||| S:938 E:944 ||| NNS
,  ||| S:944 E:946 ||| ,
and  ||| S:946 E:950 ||| CC
the  ||| S:950 E:954 ||| DT
median  ||| S:954 E:961 ||| JJ
number  ||| S:961 E:968 ||| NN
of  ||| S:968 E:971 ||| IN
serum  ||| S:971 E:977 ||| JJ
samples  ||| S:977 E:985 ||| NNS
per  ||| S:985 E:989 ||| IN
patient  ||| S:989 E:997 ||| NN
was  ||| S:997 E:1001 ||| VBD
10 ||| S:1001 E:1003 ||| CD
.  ||| S:1003 E:1005 ||| .
At  ||| S:1005 E:1008 ||| IN
baseline ||| S:1008 E:1016 ||| NN
,  ||| S:1016 E:1018 ||| ,
the  ||| S:1018 E:1022 ||| DT
correlation  ||| S:1022 E:1034 ||| NN
between  ||| S:1034 E:1042 ||| IN
the  ||| S:1042 E:1046 ||| DT
levels  ||| S:1046 E:1053 ||| NNS
of  ||| S:1053 E:1056 ||| IN
ANCA  ||| S:1056 E:1061 ||| NNP
against  ||| S:1061 E:1069 ||| IN
PR3  ||| S:1069 E:1073 ||| NNP
and  ||| S:1073 E:1077 ||| CC
against  ||| S:1077 E:1085 ||| IN
all  ||| S:1085 E:1089 ||| PDT
the  ||| S:1089 E:1093 ||| DT
deglycosylated  ||| S:1093 E:1108 ||| JJ
recombinant  ||| S:1108 E:1120 ||| JJ
variants  ||| S:1120 E:1129 ||| NN
of  ||| S:1129 E:1132 ||| IN
PR3  ||| S:1132 E:1136 ||| NNP
were  ||| S:1136 E:1141 ||| VBD
greater  ||| S:1141 E:1149 ||| JJR
than  ||| S:1149 E:1154 ||| IN
0.94  ||| S:1154 E:1159 ||| CD
( ||| S:1159 E:1160 ||| -LRB-
?  ||| S:1160 E:1161 ||| NNP
< ||| S:1161 E:1162 ||| SYM
0.001  ||| S:1162 E:1168 ||| NNP
for  ||| S:1168 E:1172 ||| IN
all  ||| S:1172 E:1176 ||| PDT
the  ||| S:1176 E:1180 ||| DT
comparisons ||| S:1180 E:1191 ||| NNS
) ||| S:1191 E:1192 ||| -RRB-
.  ||| S:1192 E:1194 ||| .
Longitudinal  ||| S:1194 E:1207 ||| JJ
analyses  ||| S:1207 E:1216 ||| NNS
comparing  ||| S:1216 E:1226 ||| VBG
the  ||| S:1226 E:1230 ||| DT
levels  ||| S:1230 E:1237 ||| NNS
of  ||| S:1237 E:1240 ||| IN
ANCA  ||| S:1240 E:1245 ||| NNP
against  ||| S:1245 E:1253 ||| IN
PR3  ||| S:1253 E:1257 ||| CD
versus  ||| S:1257 E:1264 ||| IN
all  ||| S:1264 E:1268 ||| PDT
the  ||| S:1268 E:1272 ||| DT
deglycosylated  ||| S:1272 E:1287 ||| JJ
recombinant  ||| S:1287 E:1299 ||| JJ
variants  ||| S:1299 E:1308 ||| NN
of  ||| S:1308 E:1311 ||| IN
PR3 ||| S:1311 E:1314 ||| NNP
,  ||| S:1314 E:1316 ||| ,
using  ||| S:1316 E:1322 ||| VBG
linear  ||| S:1322 E:1329 ||| JJ
mixed  ||| S:1329 E:1335 ||| JJ
models ||| S:1335 E:1341 ||| NNS
,  ||| S:1341 E:1343 ||| ,
showed  ||| S:1343 E:1350 ||| VBD
no  ||| S:1350 E:1353 ||| DT
significant  ||| S:1353 E:1365 ||| JJ
statistical  ||| S:1365 E:1377 ||| JJ
differences  ||| S:1377 E:1389 ||| NNS
( ||| S:1389 E:1390 ||| -LRB-
rho  ||| S:1390 E:1394 ||| CD
> ||| S:1394 E:1395 ||| CD
or=0.90  ||| S:1395 E:1403 ||| CD
in  ||| S:1403 E:1406 ||| IN
all  ||| S:1406 E:1410 ||| DT
cases ||| S:1410 E:1415 ||| NNS
) ||| S:1415 E:1416 ||| -RRB-
.  ||| S:1416 E:1418 ||| .
The  ||| S:1418 E:1422 ||| DT
glycosylation  ||| S:1422 E:1436 ||| JJ
status  ||| S:1436 E:1443 ||| NN
of  ||| S:1443 E:1446 ||| IN
PR3  ||| S:1446 E:1450 ||| NNP
has  ||| S:1450 E:1454 ||| VBZ
no  ||| S:1454 E:1457 ||| DT
impact  ||| S:1457 E:1464 ||| NN
on  ||| S:1464 E:1467 ||| IN
its  ||| S:1467 E:1471 ||| PRP$
recognition  ||| S:1471 E:1483 ||| NN
by  ||| S:1483 E:1486 ||| IN
ANCA  ||| S:1486 E:1491 ||| NNP
in  ||| S:1491 E:1494 ||| IN
WG ||| S:1494 E:1496 ||| NNP
.  ||| S:1496 E:1498 ||| .
